Patents by Inventor Kai Lui
Kai Lui has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12016963Abstract: Freshening composition having at least 85% by weight of the freshening composition of water; at least 0.0015% of by weight of the freshening composition of alkoxylated phenol; and a perfume having at least 60% by weight of the perfume, Perfume Raw Materials having ClogP greater than 1.0. The alkoxylated phenol is according to Formula (I): wherein a is a value selected from 3 to 15; b is a value selected from 0 to 12; wherein the value of a+b, the degree of alkoxylation is from 3 to 15.Type: GrantFiled: May 1, 2020Date of Patent: June 25, 2024Assignee: The Procter & Gamble CompanyInventors: Michael David O'Young Mui, Kevin Lee Kott, Jennifer Lea Rinker, Bonny Kay Lui, Gregory Scot Miracle, Karunakaran Narasimhan, George Kavin Morgan, III, David Wesley Brogden, Jennifer Beth Allison, Andrea C. Keenan, Daniel S. Miller, Theodore Tysak, Raymond Schill
-
Patent number: 11051871Abstract: Nanosecond pulsed electric field (nsPEF) treatments of a tumor are adjusted based on a size and type of the tumor to stimulate an immune response against the tumor and other tumors in the subject. Calreticulin expression on tumor cells can be detected to confirm treatment. An immune response biomarker can be measured, and further nsPEF treatments can be performed if needed to stimulate or further stimulate the immune response. Cancers that have metastasized may be treated by directly treating a tumor that is most accessible. The treatment can be combined with CD47-blocking antibodies, doxorubicin, CTLA-4-blocking antibodies, and/or PD-1-blocking antibodies. Electrical characteristics of nsPEF treatments can be based on the size, type, and/or strength of tumors and/or a quantity of tumors in the subject.Type: GrantFiled: June 23, 2020Date of Patent: July 6, 2021Assignee: Pulse Biosciences, Inc.Inventors: Richard Lee Nuccitelli, Pamela S. Nuccitelli, Joanne Lum, Kaying Lui, Brian G. Athos, Mark P. Kreis, Zachary R. Mallon, Jon Berridge
-
Publication number: 20200353113Abstract: Freshening composition having at least 85% by weight of the freshening composition of water; at least 0.0015% of by weight of the freshening composition of alkoxylated phenol; and a perfume having at least 60% by weight of the perfume, Perfume Raw Materials having ClogP greater than 1.0. The alkoxylated phenol is according to Formula (I): wherein a is a value selected from 3 to 15; b is a value selected from 0 to 12; wherein the value of a+b, the degree of alkoxylation is from 3 to 15.Type: ApplicationFiled: May 1, 2020Publication date: November 12, 2020Inventors: Michael David O'Young MUI, Kevin Lee KOTT, Jennifer Lea RINKER, Bonny Kay LUI, Gregory Scot MIRACLE, Karunakaran NARASIMHAN, George Kavin MORGAN, III, David Wesley BROGDEN, Jennifer Beth ALLISON, Andrea C. KEENAN, Daniel S. MILLER, Theodore TYSAK, Raymond SCHILL
-
Publication number: 20200315687Abstract: Nanosecond pulsed electric field (nsPEF) treatments of a tumor are adjusted based on a size and type of the tumor to stimulate an immune response against the tumor and other tumors in the subject. Calreticulin expression on tumor cells can be detected to confirm treatment. An immune response biomarker can be measured, and further nsPEF treatments can be performed if needed to stimulate or further stimulate the immune response. Cancers that have metastasized may be treated by directly treating a tumor that is most accessible. The treatment can be combined with CD47-blocking antibodies, doxorubicin, CTLA-4-blocking antibodies, and/or PD-1-blocking antibodies. Electrical characteristics of nsPEF treatments can be based on the size, type, and/or strength of tumors and/or a quantity of tumors in the subject.Type: ApplicationFiled: June 23, 2020Publication date: October 8, 2020Applicant: Pulse Biosciences, Inc.Inventors: Richard Lee Nuccitelli, Pamela S. Nuccitelli, Joanne Lum, Kaying Lui, Brian G. Athos, Mark P. Kreis, Zachary R. Mallon, Jon Berridge
-
Patent number: 10729724Abstract: Nanosecond pulsed electric field (nsPEF) treatments of a tumor are adjusted based on a size and type of the tumor to stimulate an immune response against the tumor and other tumors in the subject. Calreticulin expression on tumor cells can be detected to confirm treatment. An immune response biomarker can be measured, and further nsPEF treatments can be performed if needed to stimulate or further stimulate the immune response. Cancers that have metastasized may be treated by directly treating a tumor that is most accessible. The treatment can be combined with CD47-blocking antibodies, doxorubicin, CTLA-4-blocking antibodies, and/or PD-1-blocking antibodies. Electrical characteristics of nsPEF treatments can be based on the size, type, and/or strength of tumors and/or a quantity of tumors in the subject.Type: GrantFiled: July 11, 2019Date of Patent: August 4, 2020Assignee: Pulse Biosciences, Inc.Inventors: Richard Lee Nuccitelli, Pamela S. Nuccitelli, Joanne Lum, Kaying Lui, Brian G. Athos, Mark P. Kreis, Zachary R. Mallon, Jon Berridge
-
Publication number: 20190350971Abstract: Nanosecond pulsed electric field (nsPEF) treatments of a tumor are adjusted based on a size and type of the tumor to stimulate an immune response against the tumor and other tumors in the subject. Calreticulin expression on tumor cells can be detected to confirm treatment. An immune response biomarker can be measured, and further nsPEF treatments can be performed if needed to stimulate or further stimulate the immune response. Cancers that have metastasized may be treated by directly treating a tumor that is most accessible. The treatment can be combined with CD47-blocking antibodies, doxorubicin, CTLA-4-blocking antibodies, and/or PD-1-blocking antibodies. Electrical characteristics of nsPEF treatments can be based on the size, type, and/or strength of tumors and/or a quantity of tumors in the subject.Type: ApplicationFiled: July 11, 2019Publication date: November 21, 2019Applicant: Pulse Biosciences, Inc.Inventors: Richard Lee Nuccitelli, Pamela S. Nuccitelli, Joanne Lum, Kaying Lui, Brian G. Athos, Mark P. Kreis, Zachary R. Mallon, Jon Berridge
-
Patent number: 10391125Abstract: Nanosecond pulsed electric field (nsPEF) treatments of a tumor are adjusted based on a size and type of the tumor to stimulate an immune response against the tumor and other tumors in the subject. Calreticulin expression on tumor cells can be detected to confirm treatment. An immune response biomarker can be measured, and further nsPEF treatments can be performed if needed to stimulate or further stimulate the immune response. Cancers that have metastasized may be treated by directly treating a tumor that is most accessible. The treatment can be combined with CD47-blocking antibodies, doxorubicin, CTLA-4-blocking antibodies, and/or PD-1-blocking antibodies. Electrical characteristics of nsPEF treatments can be based on the size, type, and/or strength of tumors and/or a quantity of tumors in the subject.Type: GrantFiled: September 26, 2018Date of Patent: August 27, 2019Assignee: PULSE BIOSCIENCES, INC.Inventors: Richard Lee Nuccitelli, Pamela S. Nuccitelli, Joanne Lum, Kaying Lui, Brian G. Athos, Mark P. Kreis, Zachary R. Mallon, Jon Berridge
-
Publication number: 20190022141Abstract: Nanosecond pulsed electric field (nsPEF) treatments of a tumor are adjusted based on a size and type of the tumor to stimulate an immune response against the tumor and other tumors in the subject. Calreticulin expression on tumor cells can be detected to confirm treatment. An immune response biomarker can be measured, and further nsPEF treatments can be performed if needed to stimulate or further stimulate the immune response. Cancers that have metastasized may be treated by directly treating a tumor that is most accessible. The treatment can be combined with CD47-blocking antibodies, doxorubicin, CTLA-4-blocking antibodies, and/or PD-1-blocking antibodies. Electrical characteristics of nsPEF treatments can be based on the size, type, and/or strength of tumors and/or a quantity of tumors in the subject.Type: ApplicationFiled: September 26, 2018Publication date: January 24, 2019Applicant: Pulse Biosciences, Inc.Inventors: Richard Lee Nuccitelli, Pamela S. Nuccitelli, Joanne Lum, Kaying Lui, Brian G. Athos, Mark P. Kreis, Zachary R. Mallon, Jon Berridge
-
Patent number: 10137152Abstract: A subject is inoculated from a disease by exposing a biopsy of a tumor or other abnormal growth to a nanosecond pulsed electric field (nsPEF). A sufficient treatment can be confirmed by detecting calreticulin on the tumor cell membranes, which indicates apoptosis occurring in the tumor cells. Treated tumor cells from the biopsy are then reintroduced into the subject. The calreticulin-exhibiting tumor cells activate the subject's immune system against the tumor, and any other like tumors in the body, and effectively vaccinates the subject against the disease. The treatment can be combined with CD47-blocking antibodies, doxorubicin, CTLA-4-blocking antibodies, and/or PD-1-blocking antibodies. The immune response may be measured at a later time. Specific electrical characteristics of the nsPEF treatments can be based on the type and/or strength of the tumor.Type: GrantFiled: January 17, 2018Date of Patent: November 27, 2018Assignee: Pulse Biosciences, Inc.Inventors: Richard Lee Nuccitelli, Pamela S. Nuccitelli, Joanne Lum, Kaying Lui, Brian G. Athos, Mark P. Kreis, Zachary R. Mallon, Jon Berridge
-
Publication number: 20180153937Abstract: A subject is inoculated from a disease by exposing a biopsy of a tumor or other abnormal growth to a nanosecond pulsed electric field (nsPEF). A sufficient treatment can be confirmed by detecting calreticulin on the tumor cell membranes, which indicates apoptosis occurring in the tumor cells. Treated tumor cells from the biopsy are then reintroduced into the subject. The calreticulin-exhibiting tumor cells activate the subject's immune system against the tumor, and any other like tumors in the body, and effectively vaccinates the subject against the disease. The treatment can be combined with CD47-blocking antibodies, doxorubicin, CTLA-4-blocking antibodies, and/or PD-1-blocking antibodies. The immune response may be measured at a later time. Specific electrical characteristics of the nsPEF treatments can be based on the type and/or strength of the tumor.Type: ApplicationFiled: January 17, 2018Publication date: June 7, 2018Applicant: Pulse Biosciences, Inc.Inventors: Richard Lee Nuccitelli, Pamela S. Nuccitelli, Joanne Lum, Kaying Lui, Brian G. Athos, Mark P. Kreis, Zachary R. Mallon, Jon Berridge
-
Publication number: 20170216353Abstract: A subject is inoculated from a disease by exposing a biopsy of a tumor or other abnormal growth to a nanosecond pulsed electric field (nsPEF). A sufficient treatment can be confirmed by detecting calreticulin on the tumor cell membranes, which indicates apoptosis occurring in the tumor cells. Treated tumor cells from the biopsy are then reintroduced into the subject. The calreticulin-exhibiting tumor cells activate the subject's immune system against the tumor, and any other like tumors in the body, and effectively vaccinates the subject against the disease. The treatment can be combined with CD47-blocking antibodies, doxorubicin, CTLA-4-blocking antibodies, and/or PD-1-blocking antibodies. The immune response may be measured at a later time. Specific electrical characteristics of the nsPEF treatments can be based on the type and/or strength of the tumor.Type: ApplicationFiled: April 11, 2017Publication date: August 3, 2017Applicant: Pulse Biosciences, Inc.Inventors: Richard Lee Nuccitelli, Pamela S. Nuccitelli, Joanne Lum, Kaying Lui, Brian G. Athos, Mark P. Kreis, Zachary R. Mallon, Jon Berridge
-
Patent number: 9656066Abstract: Nanosecond pulsed electric field (nsPEF) treatments of a tumor are adjusted based on size and type of a tumor to stimulate an immune response against the tumor and other tumors in a subject. Calreticulin expression on tumor cells can be detected to confirm treatment. An immune response biomarker can be measured, and further nsPEF treatments can be performed if needed to stimulate or further stimulate the immune response. Cancers that have metastasized may be treated by directly treating a tumor that is most accessible. The treatment can be combined with CD47-blocking antibodies, doxorubicin, CTLA-4-blocking antibodies, and/or PD-1-blocking antibodies. Electrical characteristics of nsPEF treatments can be based on the size, type, and/or strength of tumors and/or a quantity of tumors in the subject.Type: GrantFiled: July 22, 2015Date of Patent: May 23, 2017Assignee: PULSE BIOSCIENCES, INC.Inventors: Richard Lee Nuccitelli, Pamela Nuccitelli, Joanne Lum, Kaying Lui, Brian Athos, Mark Kreis, Zachary Mallon, Jon Berridge
-
Publication number: 20170117690Abstract: An electric vehicle for routing inspection of power transmission lines, includes a body; a running mechanism mounted to the body, comprising a front wheel and a rear wheel connected by a cross beam and rolling on the cable; an obstacle sensor and a cam rotatably mounted to the cross beam, the cam rotating to roll onto the cable after an obstacle is detected on the cable such that the front wheel is raised to a position above the cable, and the cam continuing rolling on the cable after the front wheel passes the obstacle such that the front portion of the cross beam falls back downwards and the front wheel then falls back onto the cable, a hanging seat rotatably hanging to the body and a control device at least partially disposed in the hanging seat and comprising a braking device.Type: ApplicationFiled: December 15, 2015Publication date: April 27, 2017Applicants: State Grid Corporation of China, Wuxi Electric Power Company of Jiangsu Electric Power CorporationInventors: Liping HUANG, Xu WENG, Haiping SHEN, Wenjun JIANG, Ting LIU, Kai LUI, Pan TANG, Hongjun CHEN
-
Publication number: 20170081613Abstract: A cleaning composition containing an amphiphilic graft polymer and a sulfonate group-containing copolymer is provided, which exhibits significant improved whiteness maintenance benefit when used to treat fabrics.Type: ApplicationFiled: September 23, 2015Publication date: March 23, 2017Inventors: Xiaoli WANG, Xianling ZHAI, Peng QIN, Xiaoyan LIU, Mark Allen SMERZNAK, Patrick Christopher STENGER, Bonny Kay LUI, Praveen Kumar DEPA, William Coffin SHEAROUSE, Stacey Lee VOSTERS, Rachel Marie HILER, Akiko HEMMI, Hirotaka MIZOGUCHI, Rika MATSUMOTO
-
Publication number: 20160090554Abstract: A cleaning composition containing an alkoxylated polyalkyleneimine and a sulfonate group-containing copolymer is provided, which exhibits significant improved whiteness maintenance benefit when used to treat fabrics.Type: ApplicationFiled: September 23, 2015Publication date: March 31, 2016Inventors: Xiaoli WANG, Xianling ZHAI, Peng QIN, Xiaoyan LIU, Mark Allen SMERZNAK, Patrick Christopher STENGER, Bonny Kay LUI, Praveen Kumar DEPA, William Coffin SHEAROUSE, Stacey Lee VOSTERS, Rachel Marie HILER, Akiko HEMMI, Hirotaka MIZOGUCHI, Rika MATSUMOTO
-
Publication number: 20150320999Abstract: Nanosecond pulsed electric field (nsPEF) treatments of a tumor are adjusted based on size and type of a tumor to stimulate an immune response against the tumor and other tumors in a subject. Calreticulin expression on tumor cells can be detected to confirm treatment. An immune response biomarker can be measured, and further nsPEF treatments can be performed if needed to stimulate or further stimulate the immune response. Cancers that have metastasized may be treated by directly treating a tumor that is most accessible. The treatment can be combined with CD47-blocking antibodies, doxorubicin, CTLA-4-blocking antibodies, and/or PD-1-blocking antibodies. Electrical characteristics of nsPEF treatments can be based on the size, type, and/or strength of tumors and/or a quantity of tumors in the subject.Type: ApplicationFiled: July 22, 2015Publication date: November 12, 2015Applicant: NanoBlate Corp.Inventors: Richard Lee Nuccitelli, Pamela Nuccitelli, Joanne Lum, Kaying Lui, Brian Athos, Mark Kreis, Zachary Mallon, Jon Berridge
-
Patent number: 9101764Abstract: Nanosecond pulsed electric field (nsPEF) treatments of a tumor are used to cause the tumor to express calreticulin and stimulate an immune response against the tumor and other tumors in a subject. An immune response biomarker can be measured, and further nsPEF treatments can be performed if needed to stimulate or further stimulate the immune response. Cancers that have metastasized may be treated. The treatment can be combined with CD47-blocking antibodies, doxorubicin, CTLA-4-blocking antibodies, and/or PD-1-blocking antibodies. Electrical characteristics of nsPEF treatments can be based on the size, type, and/or strength of tumors and/or a quantity of tumors in the subject.Type: GrantFiled: May 27, 2014Date of Patent: August 11, 2015Assignee: NanoBlate Corp.Inventors: Richard Lee Nuccitelli, Pamela Nuccitelli, Joanne Lum, Kaying Lui, Brian Athos, Mark Kreis, Zachary Mallon, Jon Berridge
-
Publication number: 20150160297Abstract: The present invention discloses a method for identifying the fault by current differential protection and a device thereof. The method comprises: measuring the full component currents of the two terminals of a two-terminal line system and calculating the corresponding fault component current vectors; obtaining an operate value by calculating a first difference between an absolute value of the sum of the fault component current vectors and Iset1; obtaining a restrain value by multiplying a second difference with a control factor, in which the second difference is calculated between the maximum of the absolute values of the fault component currents and Iset2 or between the absolute value of the difference of said fault component currents and Iset2; and identifying a fault as an external one or internal one by comparing the operate value with the restrain value. The solutions of the present invention achieve better reliability, sensitivity and faster speed than existing products.Type: ApplicationFiled: June 6, 2012Publication date: June 11, 2015Applicant: ABB TECHNOLOGY LTD.Inventors: Youyi Li, Kai Lui, Bin Su
-
Publication number: 20140358066Abstract: Nanosecond pulsed electric field (nsPEF) treatments of a tumor are used to cause the tumor to express calreticulin and stimulate an immune response against the tumor and other tumors in a subject. An immune response biomarker can be measured, and further nsPEF treatments can be performed if needed to stimulate or further stimulate the immune response. Cancers that have metastasized may be treated. The treatment can be combined with CD47-blocking antibodies, doxorubicin, CTLA-4-blocking antibodies, and/or PD-1-blocking antibodies. Electrical characteristics of nsPEF treatments can be based on the size, type, and/or strength of tumors and/or a quantity of tumors in the subject.Type: ApplicationFiled: May 27, 2014Publication date: December 4, 2014Applicant: NanoBlate Corp.Inventors: Richard Lee Nuccitelli, Pamela Nuccitelli, Joanne Lum, Kaying Lui, Brian Athos, Mark Kreis, Zachary Mallon, Jon Berridge
-
Publication number: 20100101614Abstract: The invention relates to a telescoping umbrella, particularly a sun or rain umbrella, having a receiving tube and a telescoping tube displaceably and lockably located therein, having an umbrella roof connected to the telescoping tube in an articulating manner, the umbrella roof being adjustable by means of a cable or Bowden wire running inside the tubes, and having an actuating device for the cable or Bowden wire, characterized in that the actuating device comprises a winch for the cable or Bowden wire, the winch being located inside the receiving tube.Type: ApplicationFiled: April 25, 2008Publication date: April 29, 2010Inventors: Zhonglin Wang, Kai Lui